Community Perspectives on JAK Inhibition for Inflammatory Bowel Disease Management: Addressing Gaps in Therapy
Post-Test/Evaluation

Questions marked with a * are required
30%
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
Are you a Physician? 
Shannon is a 27-year-old woman who presents with abdominal cramps and chronic diarrhea for the past 2 months. Evaluation shows inflammation of the colon, with no perianal nor rectal disease. She has not had prior resection and is not experiencing structuring and/or penetrating behavior. How would you assess this patient’s disease burden?
Which of the following JAK inhibitors are specifically selective for JAK1? 
In patients with moderate-severe IBD, when should advanced therapy be started? 
Jackie is a 24-year-old woman who presents to your office with the following: tenesmus; 3-4 stools/day (almost always with blood) for the last 4 weeks; abdominal tenderness; RLQ pain relieved upon defecation; pyoderma; temperature: 99.8°F; ESR: 22 mm/hr; and no tachycardia, anemia or other signs of toxicity. She is diagnosed with moderate UC. At this point, which of the following is true?  
At this time, the two JAK inhibitors upadacitinib and tofacitinib are FDA-approved for which of the following?
Powered by QuestionPro